ruxoprubart subcutaneous (NM8074 SC) / NovelMed - LARVOL DELTA

NovelMed Therapeutics Announces Regulatory Clearance for Subcutaneous Ruxoprubart and Reports Positive Phase II Intravenous Monotherapy Results in PNH (GlobeNewswire) - "SC trials are planned but have not yet been initiated. This approach is expected to reduce patient and caregiver burden by eliminating the need for IV infusions in a clinical setting."

New P2 trial • Paroxysmal Nocturnal Hemoglobinuria